Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 12/20 | 0.38 |
| ▸ | GIPR | P48546 | 11/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 7/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.38 |
| ▸ | PTPRC | P08575 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4956133 | 0.90 | GCGR (0.36) | GCGRGIPR | |
| SCHEMBL4957709 | 0.89 | GCGR (0.48) | GCGRGIPRPTPN1PTPN2 | |
| SCHEMBL4958928 | 0.84 | GCGR (0.45) | GCGRGIPRPTPN1PTPN2PTPRC | |
| SCHEMBL4954605 | 0.84 | GCGR (0.44) | GCGRGIPRPTPN1PTPN2 | |
| SCHEMBL4956103 | 0.83 | GCGR (0.45) | GCGRGIPRPTPN1PTPN2 | |
| SCHEMBL4955840 | 0.82 | GCGR (0.38) | GCGRGIPR | |
| SCHEMBL4959285 | 0.81 | GCGR (0.50) | GCGRGIPRPTPN1PTPN2 | |
| SCHEMBL4957141 | 0.81 | GCGR (0.46) | GCGRGIPRPTPN1PTPN2 | |
| SCHEMBL4957942 | 0.80 | GCGR (0.48) | GCGRGIPRPTPN1PTPN2 | |
| SCHEMBL4955239 | 0.80 | EIF4E (0.42) | GCGRGIPRPTPN1PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200371-A1 | THIAZOLE AND THIADIAZOLE INHIBITORS OF TYROSINE PHOSPHATASES | IMPINJ, INC. | 2008-08-21 | — | — | US | disclosed |
| US-7381736-B2 | Thiazole and thiadiazole inhibitors of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. (US) | 2008-06-03 | — | — | US | disclosed |
| EP-1841749-A1 | DERIVATIVES OF THIAZOLE AND THIADIAZOLE INHIBITORS OF TYROSINE PHOSPHATASES | Metabasis Therapeutics, Inc. (US) | 2007-10-10 | — | — | EP | disclosed |
| EP-1786421-A2 | OXYGEN/NITROGEN HETEROCYCLE INHIBITORS OF TYROSINE PHOSPHATASES | Cengent Therapeutics, Inc. (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20060194768-A1 | Thiazole and thiadiazole inhibitors of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2006-08-31 | — | — | US | disclosed |
| US-20060135483-A1 | Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2006-06-22 | — | — | US | disclosed |
| WO-2006028970-A1 | DERIVATIVES OF THIAZOLE AND THIADIAZOLE INHIBITORS OF TYROSINE PHOSPHATASES | CENGENT THERAPEUTICS, INC. (US) | 2006-03-16 | — | — | WO | disclosed |
| WO-2006017124-A2 | OXYGEN/NITROGEN HETEROCYCLE INHIBITORS OF TYROSINE PHOSPHATASES | CENGENT THERAPEUTICS, INC. (US) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135483-A1 | Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases | PTPRO, PTPRG, PTPN1 | GCGR 941/4885GIPR 553/4885PTPN1 3/4885 |
| US-20060194768-A1 | Thiazole and thiadiazole inhibitors of tyrosine phosphatases | PTPN1, PTPN5, PTPN18 | GCGR 2166/4885GIPR 1774/4885PTPN1 1/4885 |
| US-20080200371-A1 | THIAZOLE AND THIADIAZOLE INHIBITORS OF TYROSINE PHOSPHATASES | PTPN1, PTPN5, PTPN18 | GCGR 2166/4885GIPR 1774/4885PTPN1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.